US 10,238,657 B2Granted

Heterocyclic compounds for treating psoriasis

AssigneeJs Innopharm (Shanhai) Ltd.

InventorsJintao Zhang, Quanhai Liu, Minyu Liu, Xiaoling Huang, Yifang Deng, Pengxia Yu

Life of this patent

Estimating the term…

Abstract

Disclosed herein is a method of treating psoriasis involving the use of compound of formula I and/or a pharmaceutically acceptable salt thereof.

Claims21

Dependent claims

A method of treating psoriasis comprising administering to the patient in recognized need of such treatment, an effective amount of a compound of formula I and/or a pharmaceutically acceptable salt thereof, or an effective amount of a pharmaceutical composition comprising a compound of formula I and/or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier:

wherein:
X is N or C—R, wherein R is hydrogen, halo, alkyl, haloalkyl, —CN, or alkoxy;
Y is aryl or heteroaryl optionally substituted with at least one group selected from halo, alkyl, alkenyl, alkoxy, alkynyl, aryl, cycloalkyl, heteroaryl, heterocyclyl, —OH, —CN, —COORa, —SO2NRaRb, —CONRaRb, and —NRaRb, wherein each of the group alkyl, alkenyl, alkoxy, alkynyl, aryl, cycloalkyl, heteroaryl and heterocyclyl is optionally substituted with at least one group selected from alkoxy, alkyl, halo, OH, —CN, —COORa, —SO2NRaRb, —CONRaRb, and —NRaRb;
R2 is hydrogen, aryl, —CONRaRb, alkyl, alkoxy, —COORa, cycloalkyl, heteroaryl, or heterocyclyl;
R3 is hydrogen, alkyl, aryl, cycloalkyl, alkenyl, alkynyl, alkoxy, heteroaryl, or heterocyclyl;
wherein at least one of R2 and R3 is chosen from alkoxy, aryl, cycloalkyl, heteroaryl, and heterocyclyl;
wherein each of the alkyl, alkoxy, aryl, cycloalkyl, alkenyl, alkynyl, heteroaryl, and heterocyclyl for R2 and R3 is optionally substituted with at least one group selected from —OH, alkoxy, halo, and alkyl;
Ra and Rb are independently H, alkyl, aryl, or heteroaryl, wherein each of the alkyl, aryl, and heteroaryl is optionally substituted with at least one group selected from halo, alkyl, haloalkyl, alkoxy, —OH, and heterocyclyl optionally substituted with at least one group selected from alkyl, —C(O)-alkyl, and —SO2-alkyl;
or
Ra and Rb, together with the atoms to which they are attached, form a heterocyclic ring optionally substituted with at least one group selected from halo, alkyl, haloalkyl, alkoxy, and —OH;
and
n is 1, 2, or 3.

9 more elements

A method of treating psoriasis comprising administering to the patient in recognized need of such treatment, an effective amount of a compound and/or a pharmaceutically acceptable salt thereof, or an effective amount of a pharmaceutical composition comprising a compound and/or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier, wherein the compound is selected from (S)-2-(1-(3-chloro-4-fluorophenyl)-2-hydroxyethyl)-7-(5-phenyl-1H-pyrazolo[3,4-b]pyridin-3-yl)-3,4-dihydropyrrolo[1,2-a]pyrazin-1(2H)-one;

(R)-2-(1-(3-chloro-4-fluorophenyl)-2-hydroxyethyl)-7-(5-phenyl-1H-pyrazolo[3,4-b]pyridin-3-yl)-3,4-dihydropyrrolo[1,2-a]pyrazin-1(2H)-one;
a mixture of (S)- and (R)-2-(1-(3-chloro-4-fluorophenyl)-2-hydroxyethyl)-7-(5-phenyl-1H-pyrazolo[3,4-b]pyridin-3-yl)-3,4-dihydropyrrolo[1,2-a]pyrazin-1(2H)-one;
(R)-2-(1-(3-chlorophenyl)ethyl)-7-(5-phenyl-1H-pyrrolo[2,3-b]pyridin-3-yl)-3,4-dihydropyrrolo[1,2-a]pyrazin-1(2H)-one;
(S)-2-(1-(3-chlorophenyl)ethyl)-7-(5-phenyl-1H-pyrrolo[2,3-b]pyridin-3-yl)-3,4-dihydropyrrolo[1,2-a]pyrazin-1(2H)-one;
a mixture of (R)- and (S)-2-(1-(3-chlorophenyl)ethyl)-7-(5-phenyl-1H-pyrrolo[2,3-b]pyridin-3-yl)-3,4-dihydropyrrolo[1,2-a]pyrazin-1(2H)-one;
(R)-2-(1-(3-chlorophenyl)ethyl)-7-(5-phenyl-1H-pyrazolo[3,4-b]pyridin-3-yl)-3,4-dihydropyrrolo[1,2-a]pyrazin-1(2H)-one;
(S)-2-(1-(3-chlorophenyl)ethyl)-7-(5-phenyl-1H-pyrazolo[3,4-b]pyridin-3-yl)-3,4-dihydropyrrolo[1,2-a]pyrazin-1(2H)-one;
a mixture of (R)- and (S)-2-(1-(3-chlorophenyl)ethyl)-7-(5-phenyl-1H-pyrazolo[3,4-b]pyridin-3-yl)-3,4-dihydropyrrolo[1,2-a]pyrazin-1(2H)-one;
(S)-2-(1-(3-chlorophenyl)-2-hydroxyethyl)-7-(5-phenyl-1H-pyrrolo[2,3-b]pyridin-3-yl)-3,4-dihydropyrrolo[1,2-a]pyrazin-1(2H)-one;
(R)-2-(1-(3-chlorophenyl)-2-hydroxyethyl)-7-(5-phenyl-1H-pyrrolo[2,3-b]pyridin-3-yl)-3,4-dihydropyrrolo[1,2-a]pyrazin-1(2H)-one;
a mixture of (R)- and (S)-2-(1-(3-chlorophenyl)-2-hydroxyethyl)-7-(5-phenyl-1H-pyrrolo[2,3-b]pyridin-3-yl)-3,4-dihydropyrrolo[1,2-a]pyrazin-1(2H)-one;
(S)-7-(2-((2-chloro-4-fluorophenyl)amino)-5-methylpyrimidin-4-yl)-2-(1-(3-chlorophenyl)-2-hydroxyethyl)-3,4-dihydropyrrolo[1,2-a]pyrazin-1(2H)-one;
(R)-7-(2-((2-chloro-4-fluorophenyl)amino)-5-methylpyrimidin-4-yl)-2-(1-(3-chlorophenyl)-2-hydroxyethyl)-3,4-dihydropyrrolo[1,2-a]pyrazin-1(2H)-one;
a mixture of (R)— and (S)-7-(2-((2-chloro-4-fluorophenyl)amino)-5-methylpyrimidin-4-yl)-2-(1-(3-chlorophenyl)-2-hydroxyethyl)-3,4-dihydropyrrolo[1,2-a]pyrazin-1(2H)-one;
(R)-7-(2-((2-chloro-4-fluorophenyl)amino)-5-methylpyrimidin-4-yl)-2-(1-(3-chlorophenyl)ethyl)-3,4-dihydropyrrolo[1,2-a]pyrazin-1(2H)-one;
(S)-7-(2-((2-chloro-4-fluorophenyl)amino)-5-methylpyrimidin-4-yl)-2-(1-(3-chlorophenyl)ethyl)-3,4-dihydropyrrolo[1,2-a]pyrazin-1(2H)-one;
a mixture of (R)- and (S)-7-(2-((2-chloro-4-fluorophenyl)amino)-5-methylpyrimidin-4-yl)-2-(1-(3-chlorophenyl)ethyl)-3,4-dihydropyrrolo[1,2-a]pyrazin-1(2H)-one;
(S)-8-(2-((2-chloro-4-fluorophenyl)amino)-5-methylpyrimidin-4-yl)-2-(1-(3-chlorophenyl)-2-hydroxyethyl)-2,3,4,5-tetrahydro-1H-pyrrolo[1,2-a][1,4]diazepin-1-one;
(R)-8-(2-((2-chloro-4-fluorophenyl)amino)-5-methylpyrimidin-4-yl)-2-(1-(3-chlorophenyl)-2-hydroxyethyl)-2,3,4,5-tetrahydro-1H-pyrrolo[1,2-a][1,4]diazepin-1-one;
a mixture of (R)- and (S)-8-(2-((2-chloro-4-fluorophenyl)amino)-5-methylpyrimidin-4-yl)-2-(1-(3-chlorophenyl)-2-hydroxyethyl)-2,3,4,5-tetrahydro-1H-pyrrolo[1,2-a][1,4]diazepin-1-one;
(S)-7-(2-((2-chloro-4-fluorophenyl)amino)-5-methylpyrimidin-4-yl)-2-(1-(4-chlorophenyl)-2-hydroxyethyl)-3,4-dihydropyrrolo[1,2-a]pyrazin-1(2H)-one;
(R)-7-(2-((2-chloro-4-fluorophenyl)amino)-5-methylpyrimidin-4-yl)-2-(1-(4-chlorophenyl)-2-hydroxyethyl)-3,4-dihydropyrrolo[1,2-a]pyrazin-1(2H)-one;
a mixture of (R)- and (S)-7-(2-((2-chloro-4-fluorophenyl)amino)-5-methylpyrimidin-4-yl)-2-(1-(4-chlorophenyl)-2-hydroxyethyl)-3,4-dihydropyrrolo[1,2-a]pyrazin-1(2H)-one;
(S)-7-(2-((2-chloro-4-fluorophenyl)amino)-5-methylpyrimidin-4-yl)-2-(1-(3-fluorophenyl)-2-hydroxyethyl)-3,4-dihydropyrrolo[1,2-a]pyrazin-1(2H)-one;
(R)-7-(2-((2-chloro-4-fluorophenyl)amino)-5-methylpyrimidin-4-yl)-2-(1-(3-fluorophenyl)-2-hydroxyethyl)-3,4-dihydropyrrolo[1,2-a]pyrazin-1(2H)-one;
A mixture of (R)- and (S)-7-(2-((2-chloro-4-fluorophenyl)amino)-5-methylpyrimidin-4-yl)-2-(1-(3-fluorophenyl)-2-hydroxyethyl)-3,4-dihydropyrrolo[1,2-a]pyrazin-1(2H)-one;
(S)-7-(2-((2-chloro-4-fluorophenyl)amino)-5-methylpyrimidin-4-yl)-2-(1-(4-fluorophenyl)-2-hydroxyethyl)-3,4-dihydropyrrolo[1,2-a]pyrazin-1(2H)-one;
(R)-7-(2-((2-chloro-4-fluorophenyl)amino)-5-methylpyrimidin-4-yl)-2-(1-(4-fluorophenyl)-2-hydroxyethyl)-3,4-dihydropyrrolo[1,2-a]pyrazin-1(2H)-one;
a mixture of (R)- and (S)-7-(2-((2-chloro-4-fluorophenyl)amino)-5-methylpyrimidin-4-yl)-2-(1-(4-fluorophenyl)-2-hydroxyethyl)-3,4-dihydropyrrolo[1,2-a]pyrazin-1(2H)-one;
(S)-7-(2-((2-chloro-4-(piperazin-1-yl)phenyl)amino)-5-methylpyrimidin-4-yl)-2-(1-(3-chlorophenyl)-2-hydroxyethyl)-3,4-dihydropyrrolo[1,2-a]pyrazin-1(2H)-one;
(R)-7-(2-((2-chloro-4-(piperazin-1-yl)phenyl)amino)-5-methylpyrimidin-4-yl)-2-(1-(3-chlorophenyl)-2-hydroxyethyl)-3,4-dihydropyrrolo[1,2-a]pyrazin-1(2H)-one;
a mixture of (R)- and (S)-7-(2-((2-chloro-4-(piperazin-1-yl)phenyl)amino)-5-methylpyrimidin-4-yl)-2-(1-(3-chlorophenyl)-2-hydroxyethyl)-3,4-dihydropyrrolo[1,2-a]pyrazin-1(2H)-one;
(S)-7-(2-((2-chloro-4-(piperidin-4-yl)phenyl)amino)-5-methylpyrimidin-4-yl)-2-(1-(3-chlorophenyl)-2-hydroxyethyl)-3,4-dihydropyrrolo[1,2-a]pyrazin-1(2H)-one;
(R)-7-(2-((2-chloro-4-(piperidin-4-yl)phenyl)amino)-5-methylpyrimidin-4-yl)-2-(1-(3-chlorophenyl)-2-hydroxyethyl)-3,4-dihydropyrrolo[1,2-a]pyrazin-1(2H)-one;
a mixture of (R)- and (S)-7-(2-((2-chloro-4-(piperidin-4-yl)phenyl)amino)-5-methylpyrimidin-4-yl)-2-(1-(3-chlorophenyl)-2-hydroxyethyl)-3,4-dihydropyrrolo[1,2-a]pyrazin-1(2H)-one;
(S)-7-(2-((2-chloro-4-(1-isopropylpiperidin-4-yl)phenyl)amino)-5-methylpyrimidin-4-yl)-2-(1-(3-chlorophenyl)-2-hydroxyethyl)-3,4-dihydropyrrolo[1,2-a]pyrazin-1(2H)-one;
(R)-7-(2-((2-chloro-4-(1-isopropylpiperidin-4-yl)phenyl)amino)-5-methylpyrimidin-4-yl)-2-(1-(3-chlorophenyl)-2-hydroxyethyl)-3,4-dihydropyrrolo[1,2-a]pyrazin-1(2H)-one;
a mixture of (R)- and (S)-7-(2-((2-chloro-4-(1-isopropylpiperidin-4-yl)phenyl)amino)-5-methylpyrimidin-4-yl)-2-(1-(3-chlorophenyl)-2-hydroxyethyl)-3,4-dihydropyrrolo[1,2-a]pyrazin-1(2H)-one;
(S)-7-(2-((2-chloro-4-(1-(methylsulfonyl)piperidin-4-yl)phenyl)amino)-5-methylpyrimidin-4-yl)-2-(1-(3-chlorophenyl)-2-hydroxyethyl)-3,4-dihydropyrrolo[1,2-a]pyrazin-1(2H)-one;
(R)-7-(2-((2-chloro-4-(1-(methylsulfonyl)piperidin-4-yl)phenyl)amino)-5-methylpyrimidin-4-yl)-2-(1-(3-chlorophenyl)-2-hydroxyethyl)-3,4-dihydropyrrolo[1,2-a]pyrazin-1(2H)-one;
a mixture of (R)- and (S)-7-(2-((2-chloro-4-(1-(methylsulfonyl)piperidin-4-yl)phenyl)amino)-5-methylpyrimidin-4-yl)-2-(1-(3-chlorophenyl)-2-hydroxyethyl)-3,4-dihydropyrrolo[1,2-a]pyrazin-1(2H)-one;
(S)-7-(2-((2-chloro-4-(4-isopropylpiperazin-1-yl)phenyl)amino)-5-methylpyrimidin-4-yl)-2-(1-(3-chlorophenyl)-2-hydroxyethyl)-3,4-dihydropyrrolo[1,2-a]pyrazin-1(2H)-one;
(R)-7-(2-((2-chloro-4-(4-isopropylpiperazin-1-yl)phenyl)amino)-5-methylpyrimidin-4-yl)-2-(1-(3-chlorophenyl)-2-hydroxyethyl)-3,4-dihydropyrrolo[1,2-a]pyrazin-1(2H)-one;
a mixture of (R)- and (S)-7-(2-((2-chloro-4-(4-isopropylpiperazin-1-yl)phenyl)amino)-5-methylpyrimidin-4-yl)-2-(1-(3-chlorophenyl)-2-hydroxyethyl)-3,4-dihydropyrrolo[1,2-a]pyrazin-1(2H)-one;
(S)-7-(2-((2-chloro-4-(4-(methylsulfonyl)piperazin-1-yl)phenyl)amino)-5-methylpyrimidin-4-yl)-2-(1-(3-chlorophenyl)-2-hydroxyethyl)-3,4-dihydropyrrolo[1,2-a]pyrazin-1(2H)-one;
(R)-7-(2-((2-chloro-4-(4-(methylsulfonyl)piperazin-1-yl)phenyl)amino)-5-methylpyrimidin-4-yl)-2-(1-(3-chlorophenyl)-2-hydroxyethyl)-3,4-dihydropyrrolo[1,2-a]pyrazin-1(2H)-one;
a mixture of (R)- and (S)-7-(2-((2-chloro-4-(4-(methylsulfonyl)piperazin-1-yl)phenyl)amino)-5-methylpyrimidin-4-yl)-2-(1-(3-chlorophenyl)-2-hydroxyethyl)-3,4-dihydropyrrolo[1,2-a]pyrazin-1(2H)-one;
(S)-2-(1-(3-chlorophenyl)-2-hydroxyethyl)-7-(2-((4-fluorophenyl)amino)-5-methylpyrimidin-4-yl)-3,4-dihydropyrrolo[1,2-a]pyrazin-1(2H)-one;
(R)-2-(1-(3-chlorophenyl)-2-hydroxyethyl)-7-(2-((4-fluorophenyl)amino)-5-methylpyrimidin-4-yl)-3,4-dihydropyrrolo[1,2-a]pyrazin-1(2H)-one;
a mixture of (R)- and (S)-2-(1-(3-chlorophenyl)-2-hydroxyethyl)-7-(2-((4-fluorophenyl)amino)-5-methylpyrimidin-4-yl)-3,4-dihydropyrrolo[1,2-a]pyrazin-1(2H)-one;
(S)-2-(1-(3-chlorophenyl)-2-hydroxyethyl)-7-(5-methyl-2-((tetrahydro-2H-pyran-4-yl)amino)pyrimidin-4-yl)-3,4-dihydropyrrolo[1,2-a]pyrazin-1(2H)-one;
(R)-2-(1-(3-chlorophenyl)-2-hydroxyethyl)-7-(5-methyl-2-((tetrahydro-2H-pyran-4-yl)amino)pyrimidin-4-yl)-3,4-dihydropyrrolo[1,2-a]pyrazin-1(2H)-one;
a mixture of (R)- and (S)-2-(1-(3-chlorophenyl)-2-hydroxyethyl)-7-(5-methyl-2-((tetrahydro-2H-pyran-4-yl)amino)pyrimidin-4-yl)-3,4-dihydropyrrolo[1,2-a]pyrazin-1(2H)-one;
(R)-2-((4-chloro-3-fluorophenyl)(1-methyl-1H-pyrazol-4-yl)methyl)-7-(5-methyl-2-((tetrahydro-2H-pyran-4-yl)amino)pyrimidin-4-yl)-3,4-dihydropyrrolo[1,2-a]pyrazin-1(2H)-one;
(S)-2-((4-chloro-3-fluorophenyl)(1-methyl-1H-pyrazol-4-yl)methyl)-7-(5-methyl-2-((tetrahydro-2H-pyran-4-yl)amino)pyrimidin-4-yl)-3,4-dihydropyrrolo[1,2-a]pyrazin-1(2H)-one;
a mixture of (R)- and (S)-2-((4-chloro-3-fluorophenyl)(1-methyl-1H-pyrazol-4-yl)methyl)-7-(5-methyl-2-((tetrahydro-2H-pyran-4-yl)amino)pyrimidin-4-yl)-3,4-dihydropyrrolo[1,2-a]pyrazin-1(2H)-one;
(S)-2-(1-(3-chlorophenyl)-2-hydroxyethyl)-7-(2-(cyclohexylamino)-5-methylpyrimidin-4-yl)-3,4-dihydropyrrolo[1,2-a]pyrazin-1(2H)-one;
(R)-2-(1-(3-chlorophenyl)-2-hydroxyethyl)-7-(2-(cyclohexylamino)-5-methylpyrimidin-4-yl)-3,4-dihydropyrrolo[1,2-a]pyrazin-1(2H)-one;
a mixture of (R)- and (S)-2-(1-(3-chlorophenyl)-2-hydroxyethyl)-7-(2-(cyclohexylamino)-5-methylpyrimidin-4-yl)-3,4-dihydropyrrolo[1,2-a]pyrazin-1(2H)-one;
(S)-2-(1-(3-chlorophenyl)-2-hydroxyethyl)-7-(5-methyl-2-((1-(methylsulfonyl)piperidin-4-yl)amino)pyrimidin-4-yl)-3,4-dihydropyrrolo[1,2-a]pyrazin-1(2H)-one;
(R)-2-(1-(3-chlorophenyl)-2-hydroxyethyl)-7-(5-methyl-2-((1-(methylsulfonyl)piperidin-4-yl)amino)pyrimidin-4-yl)-3,4-dihydropyrrolo[1,2-a]pyrazin-1(2H)-one;
and
a mixture of (R)- and (S)-2-(1-(3-chlorophenyl)-2-hydroxyethyl)-7-(5-methyl-2-((1-(methylsulfonyl)piperidin-4-yl)amino)pyrimidin-4-yl)-3,4-dihydropyrrolo[1,2-a]pyrazin-1(2H)-one.

60 more elements

Dependencies are inferred from the claim text.

Facts

Application: 15/578,934Filed 3 Jun 2015
Published: US 2018/0169096 A121 Jun 2018
Granted: 26 Mar 2019
Term ends: Not estimatedThe source records don’t support an estimate.

Classification9 codes

A61K 31/506
Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim: not condensed and containing further heterocyclic rings
A61K 31/4985
Having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines: pyrazines or piperazines…
A61K 31/551
Having seven-membered rings, e.g. azelastine, pentylenetetrazole: having two nitrogen atoms, e.g. dilazep
A61P 17/06
Drugs for dermatological disorders: antipsoriatics

Family

US 2018/0169096 A1Pre-grant publication · published 21 Jun 2018
US 10,238,657 B2This patent

From the US filing history. Foreign family members aren’t listed.

Timeline

Citations

Open elsewhere

patentgrep

Loading patent…

Abstract

Disclosed herein is a method of treating psoriasis involving the use of compound of formula I and/or a pharmaceutically acceptable salt thereof.

wherein:
X is N or C—R, wherein R is hydrogen, halo, alkyl, haloalkyl, —CN, or alkoxy;
Y is aryl or heteroaryl optionally substituted with at least one group selected from halo, alkyl, alkenyl, alkoxy, alkynyl, aryl, cycloalkyl, heteroaryl, heterocyclyl, —OH, —CN, —COORa, —SO2NRaRb, —CONRaRb, and —NRaRb, wherein each of the group alkyl, alkenyl, alkoxy, alkynyl, aryl, cycloalkyl, heteroaryl and heterocyclyl is optionally substituted with at least one group selected from alkoxy, alkyl, halo, OH, —CN, —COORa, —SO2NRaRb, —CONRaRb, and —NRaRb;
R2 is hydrogen, aryl, —CONRaRb, alkyl, alkoxy, —COORa, cycloalkyl, heteroaryl, or heterocyclyl;
R3 is hydrogen, alkyl, aryl, cycloalkyl, alkenyl, alkynyl, alkoxy, heteroaryl, or heterocyclyl;
wherein at least one of R2 and R3 is chosen from alkoxy, aryl, cycloalkyl, heteroaryl, and heterocyclyl;
wherein each of the alkyl, alkoxy, aryl, cycloalkyl, alkenyl, alkynyl, heteroaryl, and heterocyclyl for R2 and R3 is optionally substituted with at least one group selected from —OH, alkoxy, halo, and alkyl;
Ra and Rb are independently H, alkyl, aryl, or heteroaryl, wherein each of the alkyl, aryl, and heteroaryl is optionally substituted with at least one group selected from halo, alkyl, haloalkyl, alkoxy, —OH, and heterocyclyl optionally substituted with at least one group selected from alkyl, —C(O)-alkyl, and —SO2-alkyl;
or
Ra and Rb, together with the atoms to which they are attached, form a heterocyclic ring optionally substituted with at least one group selected from halo, alkyl, haloalkyl, alkoxy, and —OH;
and
n is 1, 2, or 3.

9 more elements

Facts

Application

15/578,934Filed 3 Jun 2015

Published

US 2018/0169096 A121 Jun 2018

Granted

26 Mar 2019

Term ends

Not estimatedThe source records don’t support an estimate.

Classification9 codes

A61K 31/506
Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim: not condensed and containing further heterocyclic rings
A61K 31/4985
Having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines: pyrazines or piperazines…
A61K 31/551
Having seven-membered rings, e.g. azelastine, pentylenetetrazole: having two nitrogen atoms, e.g. dilazep
A61P 17/06
Drugs for dermatological disorders: antipsoriatics